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Background: Dutch guidelines indicate that treatment of pancreatic head and periampullary malignan-
cies should be started within 3 weeks of the multidisciplinary team (MDT) meeting. This study aimed to
assess the impact of time to surgery on oncological outcomes.
Methods: This was a retrospective population-based cohort study of patients with pancreatic head
and periampullary malignancies included in the Netherlands Cancer Registry. Patients scheduled for
pancreatoduodenectomy and who were discussed in an MDT meeting from May 2012 to December 2016
were eligible. Time to surgery was defined as days between the final preoperative MDT meeting and
surgery, categorized in tertiles (short interval, 18 days or less; intermediate, 19–32 days; long, 33 days or
more). Oncological outcomes included overall survival, resection rate and R0 resection rate.
Results: A total of 2027 patients were included, of whom 677, 665 and 685 had a short, intermediate
and long time interval to surgery respectively. Median time to surgery was 25 (i.q.r. 14–36) days. Longer
time to surgery was not associated with overall survival (hazard ratio 0⋅99, 95 per cent c.i. 0⋅87 to 1⋅13;
P = 0⋅929), resection rate (relative risk (RR) 0⋅96, 95 per cent c.i. 0⋅91 to 1⋅01; P = 0⋅091) or R0 resection
rate (RR 1⋅01, 0⋅94 to 1⋅09; P = 0⋅733). Patients with pancreatic ductal adenocarcinoma and a long time
interval had a lower resection rate (RR 0⋅92, 0⋅85 to 0⋅99; P = 0⋅029).
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Introduction
The best chance of long-term survival for patients with
cancer of the pancreatic head and periampullary region
is obtained by radical resection. In patients with pan-
creatic cancer, systemic chemotherapy is administered
preferentially1,2. However, up to 80 per cent of patients
with pancreatic cancer are not eligible for curative resec-
tion owing to locally advanced stage or distant metastases3.
Delay in treatment may contribute to poor progno-
sis. Surgery may be postponed for valid reasons, such as
neoadjuvant therapy or preoperative biliary drainage in
case of jaundice. Postponement of surgery for logistical
reasons is undesirable. Hypothetically, a prolonged time
to surgery may lead to progression of the disease, a lower
resection rate, and worse survival. Current studies4–11 in
the literature on time to surgery have focused on pancreatic
cancer, and the results are somewhat conflicting.
Dutch guidelines recommend that treatment be started
within 3 weeks of the final multidisciplinary team (MDT)
meeting12. The aim of this study was to evaluate the impact
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of the time interval between the final MDT meeting and
surgery on overall survival, resection rate and R0 resection
rate in patients with resectable periampullary malignancies.
Methods
This was a retrospective population-based study with data
retrieved from the Netherlands Cancer Registry (NCR),
the Dutch nationwide registry covering all 17 million
inhabitants of the Netherlands that includes data on all
patients with cancer. The NCR is linked to the nation-
wide pathology database (Pathologisch-Anatomisch Lan-
delijk Geautomatiseerd Archief (PALGA)). Completeness
of inclusion is estimated to be at least 95 per cent. The
TNM classification of malignant tumours (7th edition)13
was used to record clinical and pathological tumour stages.
Data on the vital status of patients were obtained by annual
linkage with the Municipal Personal Records Database, a
database containing personal details collected by the fed-
eral government (such as address) for the whole population
of the Netherlands.
All patients diagnosed with invasive periampullary
malignancies (including pancreatic head cancer, duodenal
cancer, ampullary cancer and distal cholangiocarci-
noma, ICD-O-3: C25⋅0, C17⋅0, C24⋅1 and C24⋅0-distal
respectively14), and who were discussed in an MDT
meeting and subsequently scheduled for pancreatoduo-
denectomy, were included. Patients treated between May
2012 and December 2016 were eligible. Patients with
missing data on the date of the preoperative MDT meet-
ing were excluded. In 2013, the NCR did not record the
dates of preoperative MDT meetings, so patients sched-
uled for pancreatoduodenectomy in 2013 were excluded.
Patients with hyperbilirubinaemia underwent preoper-
ative biliary drainage. Patients who were scheduled for
and underwent staging laparoscopy for diagnostic rea-
sons were excluded. Patients who received neoadjuvant
chemo(radio)therapy before pancreatoduodenectomy
were excluded as this was not standard treatment during
the study period; patients had neoadjuvant treatment for
pancreatic ductal adenocarcinoma (PDAC) only in studies
such as the PREOPANC RCT15, which was conducted
in the Netherlands. Approval of a medical ethics commit-
tee was not required under Dutch law, as all data were
anonymized.
Data collection
Data that were collected routinely included age, sex, loca-
tion of the last MDT meeting (treating or referring hospi-
tal), preoperative biliary drainage, annual hospital volume,
time interval from the preoperative MDT meeting and
date of surgery, clinical TNM stage, pathological TNM
stage, and margin status in patients who had a resection,
whether a resection was performed or not, postoperative
chemo(radio)therapy (including both adjuvant therapy in
patients who had a resection and palliative therapy in those
who had no resection), 30- and 90-day mortality, and over-
all survival.
Outcomes and definitions
Outcomes were overall survival, resection rate and R0
resection rate. Overall survival was defined as time in days
between surgery and death or alive vital status at 1 February
2018. Resection rate was defined as the proportion of pan-
creatoduodenectomies carried out in all patients who had
surgical exploration. R0 resection rate was defined as the
proportion of R0 resections of all resections. Margin status
was recorded as reported by the assessing pathologist. A
margin of less than 1 mm was considered a non-radical
resection.
Time interval was defined as the number of days between
the date of the last preoperative MDT meeting and the
date of surgery, and was categorized in tertiles (18 days or
less; 19–32 days; 33 days or more). Surgery included both
pancreatoduodenectomy and surgical exploration only,
when no resection was performed. Pathological diagnoses
were categorized according to the WHO classification
of tumours12 and included pancreatic ductal adenocarci-
noma of the pancreatic head (PDAC, including ICD-O-3
morphology codes 8010, 8012, 8020, 8070, 8140, 8144,
8163, 8452, 8453, 8480, 8481, 8490, 8500, 8510, 8560 and
8570), other tumours of the pancreatic head (including
ICD-O-3 morphology codes 8000 and 8550), carcinoma
of the papilla of Vater (including ICD-O-3 morphol-
ogy codes 8010, 8013, 8140, 8144, 8163, 8260, 8261,
8263, 8480, 8481, 8490 and 8500), duodenal carcinoma
(including ICD-O-3 morphology codes 8010, 8012, 8013,
8140, 8144, 8255, 8261, 8263, 8480, 8481 and 8490) and
cholangiocarcinoma (including ICD-O-3 morphology
codes 8000, 8012, 8013, 8082, 8140, 8144, 8160, 8163,
8249, 8255, 8260, 8263, 8480 and 8500). Thirty- and
90-day mortality was defined as death from any cause
within 30 and 90 days of surgery respectively. Hospi-
tal volume classification was based on the number of
pancreatoduodenectomies performed for malignancy, as
registered in the NCR. Hospital volume was categorized
in two categories: 19 or less and 20 or more procedures per
year. In the Netherlands, a minimum hospital volume of
20 pancreatoduodenectomies annually has been set since
December 2011.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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Fig. 1 Diagram showing patient selection
Patients with pancreatic head or periampullary














 Staging laparoscopy for diagnostic reason only n= 92
 Missing data on MDT meeting n= 386
Excluded (neoadjuvant chemo(radio)therapy) n= 101 
MDT, multidisciplinary team; PDAC, pancreatic ductal adenocarcinoma.























Data were analysed using IBM SPSS® Statistics for
Windows® version 22.0® (IBM, Armonk, New York,
USA). Non-normally distributed continuous data are
presented as median (i.q.r.) values and analysed with the
Kruskal–Wallis test. Categorical (binary, ordinal and nom-
inal) data are presented as frequencies with percentages
and analysed with the χ2 test and Fisher’s exact test as
appropriate. Survival was determined by Kaplan–Meier
analysis. The association between time interval and sur-
vival was analysed by Cox proportional hazards models and
expressed as hazard ratios (HRs) with 95 per cent confi-
dence intervals. Associations between time interval and the
outcomes resection rate and R0 resection rate were ana-
lysed by generalized linear models and expressed as relative
risks (RRs) with 95 per cent confidence intervals. If appli-
cable, the sandwich method with robust estimators was
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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Table 1 Characteristics of patients scheduled for pancreatoduodenectomy with a short, intermediate or long time interval to surgery








(n = 685) P‡
Patient and tumour characteristics
Age (years)* 68 (61–74) 67 (60–73) 68 (62–74) 69 (62–75) < 0⋅001§
Male sex 1144 (56⋅4) 386 (57⋅0) 366 (55⋅0) 392 (57⋅2) 0⋅672
Multidisciplinary team meeting at treating hospital 1658 (81⋅8) 555 (82⋅0) 547 (82⋅3) 556 (81⋅2) 0⋅313
Missing 76
Pathological diagnosis† <0⋅001
PDAC of pancreatic head 1158 (57⋅1) 373 (55⋅1) 385 (57⋅9) 400 (58⋅4)
Carcinoma of papilla of Vater 343 (16⋅9) 107 (15⋅8) 119 (17⋅9) 117 (17⋅1)
Cholangiocarcinoma 343 (16⋅9) 108 (16⋅0) 110 (16⋅5) 125 (18⋅2)
Duodenal carcinoma 166 (8⋅2) 87 (12⋅9) 44 (6⋅6) 35 (5⋅1)
Other carcinoma of pancreatic head 17 (0⋅8) 2 (0⋅3) 7 (1⋅1) 8 (1⋅2)
pT category 0⋅147
pT0 1 (0⋅1) 0 (0) 0 (0) 1 (0⋅2)
pT1 89 (5⋅3) 22 (3⋅9) 28 (5⋅1) 39 (7⋅1)
pT2 257 (15⋅4) 91 (16⋅1) 87 (15⋅7) 79 (14⋅5)
pT3 1124 (67⋅5) 378 (66⋅8) 369 (66⋅6) 377 (69⋅0)
pT4 182 (10⋅9) 72 (12⋅7) 64 (11⋅6) 46 (8⋅4)
pTX 13 (0⋅8) 3 (0⋅5) 6 (1⋅1) 4 (0⋅7)
Missing 361
pN category 0⋅071
pN0 510 (30⋅5) 170 (29⋅8) 168 (30⋅3) 172 (31⋅3)
pN1 1111 (66⋅4) 373 (65⋅4) 372 (67⋅1) 366 (66⋅7)
pN2 45 (2⋅7) 25 (4⋅4) 10 (1⋅8) 10 (1⋅8)
pNX 7 (0⋅4) 2 (0⋅4) 4 (0⋅7) 1 (0⋅2)
Missing 354
pM category 0⋅692
pM0 1787 (88⋅2) 600 (88⋅6) 589 (88⋅6) 598 (87⋅3)
pM1 240 (11⋅8) 77 (11⋅4) 76 (11⋅4) 87 (12⋅7)
Tumour differentiation grade 0⋅820
Well 171 (11⋅5) 56 (10⋅5) 55 (11⋅0) 60 (13⋅0)
Moderate 765 (51⋅3) 272 (51⋅2) 260 (52⋅2) 233 (50⋅3)
Poor 554 (37⋅1) 203 (38⋅2) 182 (36⋅5) 169 (36⋅5)
Undifferentiated 2 (0⋅1) 0 (0⋅0) 1 (0⋅2) 1 (0⋅2)
Missing 535
Treatment characteristics
PD volume of treating hospital 0⋅077
<20 344 (17⋅0) 132 (19⋅8) 106 (16⋅1) 106 (15⋅5)
≥20 1664 (82⋅1) 534 (80⋅2) 554 (83⋅9) 576 (84⋅5)
Missing 19 (0⋅9)
Preoperative biliary drainage 913 (45⋅0) 231 (34⋅1) 318 (47⋅8) 364 (53⋅1) < 0⋅001
Postoperative chemotherapy 97 (4⋅8) 36 (5⋅3) 29 (4⋅4) 32 (4⋅7) 0⋅704
Postoperative radiotherapy 7 (0⋅3) 3 (0⋅4) 2 (0⋅3) 2 (0⋅3) 0⋅868
30-day mortality 84 of 2021 (4⋅2) 33 of 674 (4⋅9) 22 of 662 (3⋅3) 29 of 685 (4⋅2) 0⋅352
90-day mortality 203 of 2021 (10⋅0) 76 of 674 (11⋅3) 58 of 662 (8⋅8) 69 of 685 (10⋅1) 0⋅311
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Basis for pathological diagnosis: histological confirmation of
primary tumour, including autopsy (1772 patients, 87⋅4 per cent); histological confirmation of distant metastasis only, including autopsy (150, 7⋅4 per cent);
haematological or cytological confirmation, but unclear whether this concerned cytology or histology (91, 4⋅5 per cent); clinical diagnostic tests, surgical
exploration or autopsy, without pathological confirmation (14, 0⋅7 per cent). PDAC pancreatic ductal adenocarcinoma; PD, pancreatoduodenectomy. ‡χ2
or Fisher’s exact test, except §Kruskal–Wallis test.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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≤18 days (n = 677)
Time interval
19–32 days (n = 665) P
Time interval
≥33 days (n = 685) P
Median OS (months) 16⋅8 (15⋅8, 17⋅8) 17⋅3 (15⋅9, 18⋅8) 16⋅8 (14⋅9, 18⋅9) 16⋅7 (15⋅0, 18⋅4)
Unadjusted HR 1⋅00 (reference) 0⋅95 (0⋅84, 1⋅09) 0⋅471 1⋅03 (0⋅91, 1⋅17) 0⋅618
Adjusted HR† 1⋅00 (reference) 0⋅94 (0⋅82, 1⋅07) 0⋅317 0⋅99 (0⋅87, 1⋅13) 0⋅929
Resection* 1669 (82⋅3) 569 (84⋅0) 551 (82⋅9) 549 (80⋅1)
Unadjusted RR 1⋅00 (reference) 0⋅99 (0⋅94, 1⋅04) 0⋅558 0⋅95 (0⋅91, 1⋅00) 0⋅061
Adjusted RR† 1⋅00 (reference) 0⋅99 (0⋅95, 1⋅04) 0⋅791 0⋅96 (0⋅91, 1⋅01) 0⋅091
R0 resection* 1145 of 1598 (71⋅7) 398 of 540 (73⋅7) 357 of 530 (67⋅4) 390 of 528 (73⋅9)
Unadjusted RR 1⋅00 (reference) 0⋅91 (0⋅85, 0⋅99) 0⋅023 1⋅00 (0⋅93, 1⋅08) 0⋅953
Adjusted RR‡ 1⋅00 (reference) 0⋅92 (0⋅85, 0⋅99) 0⋅032 1⋅01 (0⋅94, 1⋅09) 0⋅733
Values in parentheses are 95 per cent c.i. unless indicated otherwise; *values in parentheses are percentages. †Adjusted for age and hospital volume; ‡adjusted
for hospital volume. OS, overall survival; HR, hazard ratio; RR, relative risk.
applied16. Potential confounders were determined based
on theory, using a directed acyclic graph approach17. Age
was considered a potential confounder that may have a
causal relationship with the outcome measures of resection
rate and overall survival18. Hospital volume was considered
a potential confounder that may have a causal relation-
ship with all oncological outcome measures4,18,19. Anal-
ysis of the outcome measures was adjusted for potential
confounders. Preoperative biliary drainage was considered
an intermediate factor, because it may be a reason for
postponing surgery. As it was uncertain whether the last
MDT meeting had been before or after biliary drainage,
analyses were not adjusted for biliary drainage. Results
are presented as both unadjusted and adjusted HRs and
RRs. A two-tailed P < 0⋅050 was considered statistically sig-
nificant. A subgroup analysis was performed for patients
with PDAC.
Results
In the study period, 2606 patients with a periampullary
malignancy were scheduled for surgery (Fig. 1). After
exclusions, of 2128 patients scheduled for pancreatoduo-
denectomy, 101 had neoadjuvant chemo(radio)therapy and
were also excluded. Thus, 2027 patients were included in
the final analysis. A total of 871 patients (43⋅0 per cent)
had surgery within 3 weeks of the MDT meeting. The
median interval to surgery was 25 (i.q.r. 14–36) days. The
time interval was non-normally distributed (Fig. 2).
Patient, tumour and treatment characteristics
Patient, tumour and treatment characteristics are pre-
sented in Table 1. Patients with an intermediate or long
time interval to surgery were older (P < 0⋅001) and more
often had preoperative biliary drainage (P < 0⋅001) com-
pared with patients with a short time interval to surgery.
Overall survival, resection rate and R0 resection
rate
Outcomes are presented in Table 2. The median follow-up
was 15⋅0 (i.q.r. 7⋅3–25⋅5) months. Median overall survival
was 16⋅8 (95 per cent c.i. 15⋅8 to 17⋅8) months, the resec-
tion rate was 82⋅3 per cent, and the R0 resection rate 71⋅7
per cent. There were no statistically significant differences
in overall survival or in resection rate between patients with
a short versus an intermediate or long interval to surgery.
The R0 resection rate was lower in patients with an
intermediate interval compared with that in patients with
a short time interval to surgery (67⋅4 versus 73⋅7 per cent
respectively; unadjusted RR 0⋅91, 95 per cent c.i. 0⋅85 to
0⋅99, P = 0⋅023). After adjustment for hospital volume as
a potential confounder, the R0 resection rate was similarly
lower (RR 0⋅92, 0⋅85 to 0⋅99, P = 0⋅032). In patients with a
long time interval to surgery the R0 resection rate was 73⋅9
per cent, which was not significantly different from that in
patients with a short interval to surgery.
Subgroup analysis of patients with pancreatic
ductal adenocarcinoma
Data for the subgroup of 1158 patients (57⋅1 per cent) with
PDAC are presented in Table 3, and outcomes in Table 4.
Median follow-up was 13⋅1 (i.q.r. 5⋅9–22⋅0) months.
Median overall survival was 13⋅3 (95 per cent c.i. 12⋅3 to
14⋅4) months, the resection rate was 76⋅5 per cent, and the
R0 resection rate 62⋅4 per cent. There was no statistically
significant difference in overall survival between patients
with a short versus intermediate or long interval to surgery.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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Table 3 Characteristics of patients with pancreatic ductal adenocarcinoma† scheduled for pancreatoduodenectomy with a short,
intermediate or long time interval to surgery
Time interval to surgery (days)
Total cohort
(n = 1158) ≤18 (n = 373) 19–32 (n = 385) ≥33 (n = 400) P‡
Patient and tumour characteristics
Age (years)* 68 (62–74) 67 (60–73) 68 (62–74) 69 (63–75) 0⋅003§
Male sex 639 (55⋅2) 214 (57⋅4) 198 (51⋅4) 227 (56⋅8) 0⋅191
Multidisciplinary team meeting at treating hospital 962 (86⋅8) 313 (83⋅9) 324 (84⋅2) 325 (81⋅3) 0⋅137
Missing 50
pT category 0⋅775
pT1 28 (3⋅1) 8 (2⋅7) 7 (2⋅3) 13 (4⋅5)
pT2 82 (9⋅2) 31 (10⋅4) 28 (9⋅3) 23 (7⋅9)
pT3 734 (82⋅3) 244 (81⋅6) 248 (82⋅4) 242 (82⋅9)
pT4 35 (3⋅9) 13 (4⋅3) 12 (4⋅0) 10 (3⋅4)
pTX 13 (1⋅5) 3 (1⋅0) 6 (2⋅0) 4 (1⋅4)
Missing 266
pN category 0⋅610
pN0 210 (23⋅5) 63 (21⋅1) 72 (23⋅9) 75 (25⋅7)
pN1 676 (75⋅8) 234 (78⋅3) 226 (75⋅1) 216 (74⋅0)
pNX 6 (0⋅7) 2 (0⋅7) 3 (1⋅0) 1 (0⋅3)
Missing 266
pM category 0⋅357
pM0 979 (84⋅5) 321 (86⋅1) 328 (85⋅2) 330 (82⋅5)
pM1 179 (15⋅5) 52 (13⋅9) 57 (14⋅8) 70 (17⋅5)
Tumour differentiation grade 0⋅094
Well 86 (10⋅8) 21 (7⋅7) 28 (10⋅4) 37 (14⋅6)
Moderate 408 (51⋅2) 138 (50⋅4) 147 (54⋅4) 123 (48⋅6)
Poor 302 (37⋅9) 115 (42⋅0) 94 (34⋅8) 93 (36⋅8)
Undifferentiated 1 (0⋅1) 0 1 (0⋅4) 0
Missing 361
Treatment characteristics
PD volume of treating hospital 0⋅230
<20 215 (18⋅8) 79 (21⋅6) 68 (17⋅8) 68 (17⋅1)
≥20 930 (81⋅2) 286 (78⋅4) 315 (82⋅2) 329 (82⋅9)
Missing 13
Preoperative biliary drainage 525 (45⋅3) 128 (34⋅3) 185 (48⋅1) 212 (53⋅0) <0⋅001
Postoperative chemotherapy 74 (6⋅4) 27 (7⋅2) 22 (5⋅7) 25 (6⋅3) 0⋅685
Postoperative radiotherapy 6 (0⋅5) 3 (0⋅8) 1 (0⋅3) 2 (0⋅5) 0⋅579
30-day mortality (n = 1156) 40 (3⋅5) 15 (4⋅0) 10 (2⋅6) 15 (3⋅8) 0⋅520
90-day mortality (n = 1156) 127 (11⋅0) 48 (12⋅9) 34 (8⋅9) 45 (11⋅3) 0⋅201
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Basis for pathological diagnosis: histological confirmation of
primary tumour, including autopsy (959 patients, 82⋅8 per cent); histological confirmation of distant metastasis only, including autopsy (130; 11⋅2 per cent);
haematological or cytological confirmation, but unclear whether this concerned cytology or histology (69, 6⋅0 per cent). PD, pancreatoduodenectomy. ‡χ2
or Fisher’s exact test, except §Kruskal–Wallis test.
The resection rate was lower in patients with a long inter-
val compared with that in patients with a short time interval
to surgery (72⋅8 versus 79⋅9 per cent respectively; unad-
justed RR 0⋅91, 95 per cent c.i. 0⋅84 to 0⋅98, P = 0⋅020).
This difference persisted when adjusted for the potential
confounders age and hospital volume (RR 0⋅92, 0⋅85 to
0⋅99, P = 0⋅029).
In addition, the R0 resection rate was lower in patients
with an intermediate interval compared with that in
those with a short time interval to surgery (56⋅1 versus
65⋅6 per cent respectively; unadjusted RR 0⋅85, 95 per
cent c.i. 0⋅75 to 0⋅98, P = 0⋅019). When adjusted for the
potential confounder of hospital volume, the R0 resec-
tion rate was lower (RR 0⋅86, 0⋅76 to 0⋅99, P = 0⋅033).
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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≤18 days (n = 677)
Time interval
19–32 days (n = 665) P
Time interval
≥33 days (n = 685) P
Median OS (months) 13⋅3 (12⋅3, 14⋅4) 13⋅7 (11⋅5, 15⋅9) 13⋅2 (11⋅7, 14⋅7) 13⋅1 (11⋅3, 14⋅8)
Unadjusted HR 1⋅00 (reference) 0⋅93 (0⋅79, 1⋅10) 0⋅415 1⋅03 (0⋅88, 1⋅22) 0⋅680
Adjusted HR† 1⋅00 (reference) 0⋅90 (0⋅76, 1⋅06) 0⋅201 0⋅98 (0⋅83, 1⋅15) 0⋅814
Resection* 886 (76⋅5) 298 (79⋅9) 297 (77⋅1) 291 (72⋅8)
Unadjusted RR 1⋅00 (reference) 0⋅97 (0⋅90, 1⋅04) 0⋅357 0⋅91 (0⋅84, 0⋅99) 0⋅020
Adjusted RR† 1⋅00 (reference) 0⋅98 (0⋅90, 1⋅05) 0⋅518 0⋅92 (0⋅85, 0⋅99) 0⋅029
R0 resection* 535 of 858 (62⋅4) 189 of 288 (65⋅6) 162 of 289 (56⋅1) 184 of 281 (65⋅5)
Unadjusted RR 1⋅00 (reference) 0⋅85 (0⋅75, 0⋅98) 0⋅019 1⋅00 (0⋅89, 1⋅12) 0⋅971
Adjusted RR‡ 1⋅00 (reference) 0⋅86 (0⋅76, 0⋅99) 0⋅033 1⋅02 (0⋅90, 1⋅15) 0⋅754
Values in parentheses are 95 per cent c.i. unless indicated otherwise; *values in parentheses are percentages. †Adjusted for age and hospital volume; ‡adjusted
for hospital volume. OS, overall survival; HR, hazard ratio; RR, relative risk.
As in the total cohort, the R0 resection rate of 65⋅0 per
cent in patients with a long interval to surgery was not
significantly different from that in patients with a short
interval.
Discussion
In this population-based study including over 2000 patients
with cancer of the pancreatic head and periampullary
region scheduled for pancreatoduodenectomy, no relation-
ships were observed between the time interval from the last
MDT meeting to surgery and overall survival and resection
rate. In a subgroup analysis of patients with PDAC, resec-
tion rates were higher in those with a short interval, with no
impact on overall survival. The R0 resection rate was lower
for both the total cohort and the subgroup of patients with
PDAC with an intermediate interval to surgery, compared
with that in patients with a short interval, but this was not
found when the time interval was longer.
Time to surgery in relation to the prognosis of patients
with pancreatic and periampullary cancer has been investi-
gated in a few other studies. Results from the present study
are concordant with those of most other studies5–8,20,21,
which found a longer interval to surgery was not associ-
ated with overall survival. One single-centre study9 of 170
patients found that diagnostic delay (time from onset of
signs and symptoms to date of pathological diagnosis) was
associated with worse overall survival (HR 1⋅02, 95 per cent
c.i. 1⋅01 to 1⋅04; P < 0⋅001). In another study4 worse overall
survival was observed in patients with a time interval longer
than 1 month, but only in low-volume centres. One study10
showed that overall survival was slightly worse when the
interval to surgery was short (1–14 days), with a short time
interval related to low-volume centres. These authors con-
cluded that delays for medical optimization and referral to
high-volume surgeons might be safe.
The effect of time interval to surgery on resection rate has
been investigated in a few studies, and also showed conflict-
ing results. One study11 found a lower resection rate when
the interval was longer in patients with pancreatic can-
cer, whereas three other studies showed that time interval
was not associated with resection rate in patients with pan-
creatic cancer6, pancreatic head cancer7 or periampullary
adenocarcinoma20.
From the perspective of patients diagnosed with
resectable cancer, their quality of life seemed best when
surgery was performed as soon as possible after the indica-
tion had been set22,23. The lack of effect of time to surgery
on overall survival implies that clinicians may reassure
patients that the time interval does not affect prognosis.
For some patients, postponing surgery to allow for time
to improve their physical condition for major surgery may
improve quality of care.
The finding that patients with PDAC and a long interval
to surgery had a lower resection rate may be explained by
the aggressiveness of PDAC. These tumours may rapidly
become unresectable owing to local tumour progression
and involvement of adjacent structures, or due to distant
metastases24,25.
Survival is the most relevant oncological outcome, and
survival was similar regardless of the interval to surgery.
Some patients who had an early resection may have devel-
oped distant metastases during the early postoperative
phase. With a longer time interval, some patients may have
been spared unnecessary resection, in the sense that resec-
tion would not have improved their overall survival.
Another striking finding in patients with PDAC, also
observed in the total cohort, was that the R0 resection rate
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 884–892
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was 67⋅0 per cent with a short time interval, 56⋅3 per cent
with an intermediate interval, and then increased again to
65⋅0 per cent with a long time interval. Possibly, in the
latter group, patients with poorer tumour characteristics
may have been filtered out during the longer time interval,
resulting in a higher R0 resection rate, although this is
speculative. Overall, the interpretation of the relationship
between time interval to surgery and the resection rate of
patients with PDAC is not unambiguous.
The results of this study should be interpreted in the light
of some limitations. Time to treatment can be defined by
several starting points, such as onset of symptoms, visit to
the general practitioner, visit to the outpatient clinic, the
diagnosis established by imaging, the diagnosis established
by pathological investigation or the MDT meeting. The
authors chose the latter because these data were available
in the NCR. Choosing this time point for the definition of
time interval may have introduced bias. Prolongation of the
interval may already have occurred during the diagnostic
process, for example by preoperative biliary drainage or
referral to a specialist centre. Although the main strength
of this study is its population-based design, one of the
limitations of these registries is that detailed information is
often lacking. The timing of the MDT meeting may vary
between hospitals. Some hospitals discuss their patients in
the beginning of the diagnostic process and others at the
end, when this process and also the workup for surgery has
been completed. In patients who had biliary drainage, it is
uncertain whether the last MDT had been before or after
the drainage.
Patients who had neoadjuvant therapy were excluded
from this study. There is increasing evidence that neoad-
juvant treatment improves the prognosis of patients
with PDAC. The recently completed PREOPANC trial15,
which compared neoadjuvant chemoradiotherapy followed
by surgery and adjuvant therapy with the standard of care,
demonstrated improved overall survival. These findings
cannot be extrapolated to patients who had neoadjuvant
therapy.
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